average weight loss with glp 1 GLP-1 Medication Treatment by Healthcare Providers GLP-1 Survey: 37.5% of People

EEM is a Canadian Institutes of Health Research New Investigator (ARJ-162628) and a Diabetes Canada New Investigator and is funded by Canadian Institutes of Health Research project grant 156136

Bupropion: Dosage adjustments and personalization Bupropion dosing may look different from person to person

Diagnosis of Diabetic Gastroparesis Diabetic gastroparesis is diagnosed by the presence of upper GI symptoms suggestive of delayed gastric emptying in a diabetic patient, exclusion of mechanical obstruction that could cause upper GI symptoms and the demonstration of delayed gastric emptying

GLP-1 analogs, like exendin-4, have been demonstrated in rodent studies to decrease nicotine self-administration and to lessen withdrawal symptoms like agitation and anxiety